RecruitingNCT06800768

The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery


Sponsor

Ruijin Hospital

Enrollment

40 participants

Start Date

Feb 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to investigate the value of 68Ga-FAPI PET/CT in detecting recurrent and metastatic lesions in patients with thyroid cancer after surgery.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a new type of PET/CT scan using a tracer called 68Ga-FAPI to see if it's better at detecting cancer recurrence or spread in thyroid cancer patients who have already had surgery. **You may be eligible if...** - You have had surgery for thyroid cancer - There is clinical suspicion that your cancer may have come back or spread - You are between 18 and 80 years old - You can follow the study procedures **You may NOT be eligible if...** - You have severe heart or lung problems - You have serious bone marrow, liver, or kidney dysfunction - You have a bowel obstruction or difficulty swallowing - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06800768


Related Trials